Status:
COMPLETED
Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Renal Transplantation
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Efficacy and safety of 2 groups of treatment: everolimus in association with cyclosporine microemulsion and steroids versus everolimus in association with Enteric-coated Mycophenolate Sodium (EC-MPS) ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients who participated in and completed study CRAD001A2420
- Exclusion criteria:
- Premature study or study treatment discontinuation in CRAD001A2420 study.
- Acute rejection within the 3 months prior to inclusion
- Other protocol-defined inclusion/exclusion criteria may apply
Exclusion
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00425308
Start Date
October 1 2006
Last Update
March 30 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Paris, France